SUPPLEMENTARY MATERIALS Supplementary Results
Recently, we found that 5-carboxy indirubin derivative 7 potently inhibits FLT3 kinase (IC 50 = 8 nM) with the lack of an anti-proliferative activity against MV-4-11 which is a human leukemia cell line expressing FLT3-ITD (Supplementary Table 1 ). Interestingly, the corresponding 5-carboxy ester analogue 1 showed a potent anti-proliferative activity against MV-4-11 cells (IC 50 = 41 nM), despite its very weak FLT3 inhibitory activity. Therefore, we have tried optimization to increase the inhibitory activity against both the FLT3 kinase and the growth of MV-4-11 by further derivatization at the 3′ position of indirubin skeleton.
3′-Alkyl substitutions of indirubin oxime derivatives for other kinases have been reported to provide advantages such as a higher potency and water solubility. Because there are no reports of 3′-alkyl substituted indirubin oxime derivatives with 5-carboxylic acid or ester groups as FLT3 inhibitors, we synthesized such analogs to achieve the benefits of alkyl substitutions at the 3′ oxime position. The inhibitory effects of the 3′-substituted indirubin analogs are described in Supplementary Table  1 . In general, the alkyl substituted compounds showed increased inhibitory activities against both FLT3 and MV-4-11 compared to compounds 1 and 7. The analogues of the 5-ester substituted compound 1 showed potent inhibitory activities against the MV-4-11 cells as well as FLT3 kinase. However, the 5-carboxy derivatives (9-12) showed slightly lower inhibitory activities compared to the 5-ester analogues (3-6) even though they had potent inhibitory activities on FLT3 kinase. The FLT3 and MV-4-11 inhibition effects were dependent on the substituent at the R position. The FLT3 inhibitory activities increased in the order ethyl bromide and morpholine < N-methyl piperazine < amine, piperazine. The inhibitory activities of the substituents at the R position against MV-4-11 increased in the following order: ethyl bromide and morpholine < N-methyl piperazine, amine < piperazine. The ethyl bromide and morpholine substitutions at the R position (compound 2, 6, 8 and 12) did not have a crucial impact on inhibitory abilities against FLT3 and MV-4-11. The ethyl piperazine substituted compound 4 and 10 showed the most potent inhibitory activities against FLT3 (IC 50 = 3 and 2.5 nM) and MV-4-11 (IC 50 = 1 and 40 nM) in the each series. Moreover, compound 4 inhibited the growth of MV-4-11 cells more potently than that of CEP-701 which is a well-known FLT3 inhibitor.
Surprisingly, all the alkyl substituted series of the 5-methyl ester compound 1 showed dramatically increased inhibitory activities against on FLT3 kinase. The ethyl piperazine substituted LDD1937 showed the most potent activities against both FLT3 (IC 50 = 3 nM) and MV-4-11 (IC 50 = 1 nM) each with 1000-and 40-fold enhancing activities compared to the initial compound 1. Additionally, introduction of alkyl substituents at the 3′-oxime position of 5-carboxylic acid indirubin 7 greatly improved the inhibition effects against MV-4-11. Similar to the 5-methyl ester series, piperazine substituted compound 10 showed the most potent inhibitory effects against both FLT3 and MV-4-11. However, compound 10 showed only a moderate inhibitory activity against the MV-4-11 cells even though they had a potent inhibitory activity against FLT3 kinase. We expect that the 5-carboxylic acid derivatives are too polar to penetrate the cell membrane. To confirm this expectation, the permeability of the 5-carboxylic acid compounds should be checked.
Among the 13 compounds, compound 4 (LDD1937) (Figure1A), methyl (2Z,3E)-2′-oxo-3-((2-(piperazin-1-yl)ethoxy)imino)-[2,3′-biindolinylidene]-5′-carboxylate dihydrochloride, was selected and further characterized. As shown in Fig 1B, the IC 50 of 4 (LDD1937) against the FLT3 kinase activity was 3 nM. The IC 50 s against other kinase activities were also measured (Table 1) . There is at least a 170-fold difference in the IC 50 between FLT3 and the other kinases.
Analytical data of compounds

Methyl (2Z,3E)-3-(hydroxyimino)-2′-oxo-[2,3′-biindolinylidene]-5′-carboxylate (1)
1 H NMR (400 MHz, DMSO-d6) δ ppm 11.76-11.80 (m, 1 H), 11.05-11.10 (m, 1 H), 9.17-9.21 (m, 1 H), 8.24 (d, J = 8.01 Hz, 1H), 7.73-7.78 (m, 1H), 7.36-7.42 (m, 2H), 7.00-7.06 (m, 1H), 6.92-6.98 (m, 1H), 3.79-3.86 (m, 3H). ,3E)-3-((2-bromoethoxy)imino)-2′-oxo-[2,3′ ,3E)-3-((2-aminoethoxy) 2′,3-dioxo-[2,3′-biindolinylidene]-5′-carboxylate (16) 
Methyl (2Z
J = 8.0 Hz, 1H), 7.63 (m, 2H), 7.08 (m, 1H), 6.97 (d, J = 8.4 Hz, 1H), 4.96 (t, J = 5.6 Hz, 2H), 4.03 (t, J = 5.6 Hz, 2H).
methyl (Z)-
